Nurexone Biologic Inc NRX

CEO Dr. Lior Shaltiel and R&D Director Dr. Tali Kizhner to engage with industry, investors and scientific leaders during a concentrated week in BostonTORONTO and HAIFA, Israel, Sept. 18, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotechnology company developing exosome-based regenerative therapies, today announced a series of U.S. engagements across four major life sciences events taking place in Boston from September 2

Shareholders grant the Board discretionary authority to implement a share consolidation of up to 30:1TORONTO and HAIFA, Israel, Sept. 16, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotechnology company developing exosome-based regenerative therapies, is pleased to announce the voting results from its annual general and special meeting of the shareholders of the Company (“Shareholders”) held on Tuesday, September 15, 202

Collaboration to evaluate MicronJet™ with NurExone exosomes across ophthalmic and aesthetic applications in multi-billion-dollar marketsTORONTO and HAIFA, Israel, Sept. 14, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, announces that its Israeli subsidiary, NurExone Biologic Ltd., has entered into a Memorandum of Understanding (the “MOU”) with NanoPa

Can exosomes become both the foundation of a new regenerative therapy and a commercial business in their own right? Hello, I’m Ricki Lee, and this is another episode of The Capital Compass. Today, we’re checking back in with NurExone Biologic (USOTC:NRXBF) (TSXV:NRX), a biotech company developing exosome-based therapies for central nervous system injuries.

TORONTO and HAIFA, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotechnology company developing exosome-based regenerative therapies, is pleased to announce its financial results for the second quarter ended June 30, 2026 (“Q2”), and to provide a corporate update on its recent activities and upcoming milestones. The Company’s full set of unaudited condensed interim consolidated financial statements for th

TORONTO and HAIFA, Israel, Aug. 28, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotechnology company developing exosome-based regenerative therapies, today announced that it is scheduled to participate in the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference, taking place September 9–10, 2026, in New York City. Yoram Drucker, Co-Founder, Chairman and Vice President of Strategic Development of NurE

Proposed share consolidation of up to 30:1 intended to support potential U.S. exchange listing and broaden investor appeal TORONTO and HAIFA, Israel, Aug. 21, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (“NurExone” or the “Company”) (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) is pleased to announce that it will hold its annual general and special meeting of shareholders on September 15, 2026 (the “Meeting”) to seek shareholder approval for a special resolution authorizing the board of directors of

TORONTO, and HAIFA, Israel, Aug. 21, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce that it has closed a non-brokered private placement of 1,938,326 units (“Units”) at a price of C$0.55 per Unit for aggregate gross proceeds of approximately C$1,066,078.02 (the “Offering”), subject to final acceptance of the TSX Venture Exchange

Tissue analysis showed significantly higher numbers of myelin-positive cells in ExoPTEN-treated animals compared with controls, providing additional preclinical biological support for previously reported functional recoveryTORONTO and HAIFA, Israel, Aug. 14, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. ("NurExone" or the "Company") (TSXV: NRX, OTCQB: NRXBF, FSE: J90), a biotechnology company developing exosome-based regenerative therapies, today announced new preclinical tissue-analysis resul

The Signed MOU Targets Initial GMP Exosome Batches in H1 2027 to Support NurExone’s Clinical Pipeline and Planned Commercial ProductionTORONTO and HAIFA, Israel, Aug. 13, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. ("NurExone" or the "Company") (TSXV: NRX, OTCQB: NRXBF, FSE: J90), a biotechnology company developing exosome-based regenerative therapies, today announced that its wholly owned U.S. subsidiary, Exo-Top Inc. ("Exo-Top"), together with the Company, has signed a binding memorandum o

TORONTO, Ontario and HAIFA, Israel, June 30, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce that, subject to TSX Venture Exchange (“TSXV”) approval, it has closed a non-brokered private placement of 1,012,573 units (“Units”) at a price of C$0.62 per Unit for aggregate gross proceeds of approximately C$627,795.26 (the “Offering”)

TORONTO, Ontario and HAIFA, Israel, June 25, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce today that its wholly owned U.S. subsidiary, Exo-Top Inc. (“Exo-Top”), has entered into a binding memorandum of understanding (the “MOU”) setting out the principal commercial terms for a proposed definitive distribution agreement (the “De

French biopharma company NurExone Biologic Inc. (OTCQB:NRXBF) on Wednesday said its wholly owned U.S. subsidiary, Exo-Top Inc., entered into a binding memorandum of understanding with ExoLyra LLC outlining terms for a proposed exclusive distribution agreement in Mexico for Exo-Top’s naïve mesenchymal stem cell (MSC)-derived exosome products. The companies intend to finalize a definitive agreement within 45 calendar days. If completed, the arrangement would mark Exo-Top’s first structured commerc

Expands intellectual property protection in a strategically important market for the Company’s lead exosome-based therapy targeting nerve repair and functional recoveryTORONTO, Ontario and HAIFA, Israel, May 19, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, today announced that the Korean Ministry of Intellectual Property (“MOIP”) has issued a Notice

Sheba medical center researcher to present NurExone’s exosome optic nerve regeneration work at ISCEV@DenverTORONTO, Ontario and HAIFA, Israel, April 27, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company"), a biopharmaceutical company developing exosome-based regenerative therapies for central nervous system injuries, is pleased to announce that a patent covering the “Production of extracellular vesicles from stem cells” has been gra

TORONTO, Ontario and HAIFA, Israel, April 16, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company"), a biopharmaceutical company developing exosome-based regenerative therapies for central nervous system (“CNS”) injuries is pleased to provide a business update and reported financial results for the fourth quarter and financial year ended December 31, 2025. The Company’s lead program, ExoPTEN, is being developed for acute spinal cord i

TORONTO, Ontario and HAIFA, Israel and POMPANO BEACH, Florida, April 07, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) and BioXtek Inc. (“BioXtek”) today announced that Exo-Top Inc., NurExone’s wholly owned U.S. subsidiary, (“Exo-Top” and together, with BioXtek, the “Parties”) has entered into a non-binding letter of intent (the “LOI”) with BioXtek, a Florida-based company, to explore a strategic partnership in the field of re